Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 8 of 8 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/09/20
End: 10/30/21
Due: 10/30/22
Phase: N/A
Priority: Normal
Start: 04/24/20
End: 04/23/21
Due: 04/23/22
Phase: N/A
Priority: Normal
Start: 10/31/22
End: 08/14/23
Due: 08/14/24
Phase: N/A
Priority: Normal
Start: 10/13/20
End: 10/01/23
Due: 10/01/24
Phase: N/A
Priority: Normal
Start: 10/12/21
End: 07/28/22
Due: 07/28/23
Phase: N/A
Priority: Normal
Start: 10/09/20
End: 12/04/20
Due: 12/04/21
Phase: N/A
Priority: Normal
Start: 12/15/21
End: 05/17/23
Due: 05/17/24
Phase: N/A
Priority: Normal
Start: 06/01/22
End: 12/31/26
Due: 12/31/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| ImmuneSense Lyme Study | NCT04422314 | Adaptive Biotechnologies | user2@example.com | None | 2020-07-09 | 2021-10-30 | 2022-10-30 | - | - | 2025-07-14 |
| ImmuneRACE - Immune Response Action to COVID-19 Events | NCT04494893 | Adaptive Biotechnologies | user2@example.com | None | 2020-04-24 | 2021-04-23 | 2022-04-23 | - | - | 2025-07-14 |
| ImmuneSense™ IBD Study | NCT05769829 | Adaptive Biotechnologies | user2@example.com | None | 2022-10-31 | 2023-08-14 | 2024-08-14 | - | - | 2025-07-14 |
| The clonoSEQ® Watch Registry | NCT04545333 | Adaptive Biotechnologies | user2@example.com | None | 2020-10-13 | 2023-10-01 | 2024-10-01 | - | - | 2025-07-14 |
| ImmuneSense COVID-19 Variant Study | NCT05054088 | Adaptive Biotechnologies | user2@example.com | None | 2021-10-12 | 2022-07-28 | 2023-07-28 | - | - | 2025-07-14 |
| ImmuneSense™ COVID-19 Study | NCT04583982 | Adaptive Biotechnologies | user2@example.com | None | 2020-10-09 | 2020-12-04 | 2021-12-04 | - | - | 2025-07-14 |
| ImmuneSense™ COVID-19 Cross-Reactivity Study | NCT05112874 | Adaptive Biotechnologies | user2@example.com | None | 2021-12-15 | 2023-05-17 | 2024-05-17 | - | - | 2025-07-14 |
| Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy | NCT05255354 | Adaptive Biotechnologies | user2@example.com | None | 2022-06-01 | 2026-12-31 | 2027-12-31 | - | - | 2025-07-14 |